PNC Financial Services Group Inc. Boosts Stock Position in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

Key Points

• PNC Financial Services Group Inc. increased its stake in Genmab A/S Sponsored ADR by 34.9%, owning 100,529 shares valued at approximately $1.97 million by the end of the reporting period.
• Genmab's stock has a market capitalization of $13.75 billion, with a 52-week range between $17.24 and $27.94, as well as a P/E ratio of 10.77.
• Analysts have shown a positive outlook for Genmab, with several firms raising their price targets, and the stock currently holding an average rating of "Moderate Buy".

PNC Financial Services Group Inc. lifted its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 34.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 100,529 shares of the company's stock after purchasing an additional 26,027 shares during the quarter. PNC Financial Services Group Inc.'s holdings in Genmab A/S were worth $1,968,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. Marotta Asset Management increased its position in shares of Genmab A/S by 5.8% during the 1st quarter. Marotta Asset Management now owns 13,532 shares of the company's stock valued at $265,000 after purchasing an additional 739 shares during the last quarter. Gallacher Capital Management LLC grew its stake in shares of Genmab A/S by 6.8% during the 1st quarter. Gallacher Capital Management LLC now owns 14,346 shares of the company's stock valued at $281,000 after acquiring an additional 915 shares during the period. Laird Norton Wetherby Wealth Management LLC grew its stake in shares of Genmab A/S by 17.3% during the 4th quarter. Laird Norton Wetherby Wealth Management LLC now owns 13,711 shares of the company's stock valued at $286,000 after acquiring an additional 2,023 shares during the period. NewEdge Advisors LLC grew its stake in shares of Genmab A/S by 12.7% during the 4th quarter. NewEdge Advisors LLC now owns 19,304 shares of the company's stock valued at $403,000 after acquiring an additional 2,171 shares during the period. Finally, Barclays PLC grew its stake in shares of Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after acquiring an additional 2,285 shares during the period. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Price Performance

NASDAQ GMAB traded down $1.26 during trading on Friday, hitting $21.43. The company's stock had a trading volume of 1,745,722 shares, compared to its average volume of 1,109,862. The company has a market cap of $13.75 billion, a PE ratio of 10.77, a P/E/G ratio of 6.35 and a beta of 0.95. The business's 50 day simple moving average is $21.74 and its 200-day simple moving average is $20.86. Genmab A/S Sponsored ADR has a fifty-two week low of $17.24 and a fifty-two week high of $27.94.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. The firm had revenue of $925.00 million during the quarter, compared to analysts' expectations of $5.77 billion. Analysts expect that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Wall Street Zen upgraded Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. Truist Financial upped their price target on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $37.80.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.